SCHEMBL4458048

SCHEMBL4458048

Cc1ccc(NC(=O)c2ccc(-n3ccnc3C)c(C(F)(F)F)c2)cc1N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 3/20 0.46
KIT P10721 3/20 0.46
LYN P07948 1/20 0.46
TEK Q02763 2/20 0.45
ABL1 P00519 2/20 0.45
TRPV1 Q8NER1 1/20 0.44
KDM4E B2RXH2 1/20 0.44
POLB P06746 1/20 0.44
BRAF P15056 1/20 0.44
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
BTK Q06187 1/20 0.42
RAF1 P04049 1/20 0.42
KDR P35968 1/20 0.42
MAPK14 Q16539 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2467864 0.96 KIT (0.46) CSF1RKITLYNTEKABL1
SCHEMBL4458046 0.89 BRAF (0.49) CSF1RKITLYNTEKABL1
SCHEMBL13269565 0.81 LCK (0.52) CSF1RKITLYNABL1KDR
SCHEMBL3143280 0.79 TNK2 (0.70) KITTEKABL1KDRTNK2
SCHEMBL2357104 0.78 CSF1R (0.68) CSF1RKITLYNTEKABL1
SCHEMBL3299352 0.78 KCNQ3 (0.57) KITTEKABL1BRAFMEN1
SCHEMBL3528958 0.77 KDM4E (0.51) CSF1RKDM4E
SCHEMBL2312412 0.77 TP53 (0.67) CSF1RABL1BRAFMAPTRAF1
SCHEMBL4251502 0.77 BRAF (0.61) CSF1RBRAFMEN1NPC1MAPT
SCHEMBL3388908 0.76 BRAF (0.53) CSF1RKITLYNBRAFRAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7589101-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2009-09-15 US claimed
US-20080287432-A1 Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2008-11-20 US claimed
EP-1919924-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM, LLC (BM) 2008-05-14 EP claimed
WO-2007022268-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2007-02-22 WO claimed
US-7589101-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2009-09-15 US disclosed
US-20080287432-A1 Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2008-11-20 US disclosed
EP-1919924-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM, LLC (BM) 2008-05-14 EP disclosed
WO-2007022268-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287432-A1 Compounds and Compositions as Protein Kinase Inhibitors AURKC, PTK2B, FRK CSF1R 646/4885KIT 115/4885LYN 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.